A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one ...

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions ...

Photoacoustic imaging (PAI), renowned for its high spatial resolution and deep tissue penetration, holds great promise for disease diagnosis and molecular detection. However, the performance of ...

It is possible to infer histological and molecular features from imaging, or to interpret imaging signatures in light of known histological and molecular data.

Segmentation Outlook The contrast media injectors market is segmented based on product type, modality, application, end-user, and region. Product segments typically include single-head, dual-head, and ...

Fluorescence imaging in the second near-infrared window (NIR-II) facilitates the real-time optical contrast for in vivo biomedical imaging. However, the detection noise is an inevitable byproduct of ...

A comprehensive new study based on nationwide claims data from more than 11 million patients shows that diagnostic contrast-enhanced ultrasound (CEUS) exams are safe and can lower a patient’s ...

Noninvasive cancer imaging significantly improves diagnostics by providing comprehensive structural and functional information about tumors. Herein, we explored palladium nanoparticles loaded ...

In molecular imaging, prostate-specific membrane antigen positron emission tomography/computed tomography has shown promise in RCC, while novel tracers targeting carbonic anhydrase IX and nectin-4 are ...

BR55 is a novel molecular imaging ultrasound contrast agent designed to specifically target the vascular endothelial growth factor receptor 2 (VEGFR2), a molecule highly expressed by endothelial cells ...